Axa S.A. Acquires Shares of 38,543 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Axa S.A. bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 38,543 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,747,000. Axa S.A. owned approximately 0.06% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC lifted its position in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $28,000. Allianz SE purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $29,000. Finally, Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of recent research reports. Royal Bank of Canada decreased their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Barclays restated an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Trading Down 5.9 %

Shares of JAZZ opened at $111.17 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $6.85 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 1.04 and a beta of 0.38. The company has a 50-day moving average of $121.47 and a 200 day moving average of $122.47. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.68 EPS. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer now owns 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.